COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
dc.contributor.author | Ljungman, Per | |
dc.contributor.author | de la Camara, Rafael | |
dc.contributor.author | Mikulska, Malgorzata | |
dc.contributor.author | Tridello, Gloria | |
dc.contributor.author | Aguado, Beatriz | |
dc.contributor.author | Al Zahrani, Mohsen | |
dc.contributor.author | Apperley, Jane | |
dc.date.accessioned | 2021-06-10T19:38:26Z | |
dc.date.available | 2021-06-10T19:38:26Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 0887-6924 | |
dc.identifier.issn | 1476-5551 | |
dc.identifier.uri | https://doi.oeg/10.1038/s41375-021-01302-5 | |
dc.identifier.uri | http://hdl.handle.net/11446/4335 | |
dc.description | PubMed: 34079042 | en_US |
dc.description | WOS:000657226100001 | en_US |
dc.description.abstract | This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (-0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19. | en_US |
dc.description.sponsorship | UK NIHR Imperial College Biomedical Research Centre | en_US |
dc.description.sponsorship | We are grateful for the collaboration with the British Society for Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT). We are also grateful to all physicians, nurses, and other staff treating these patients under very challenging circumstances and still being able to help with providing data for this manuscript. JA acknowledges the support of the UK NIHR Imperial College Biomedical Research Centre. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springernature | en_US |
dc.identifier.doi | 10.1038/s41375-021-01302-5 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey | en_US |
dc.type | article | en_US |
dc.relation.journal | Leukemia | en_US |
dc.department | [0-Belirlenecek] | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.institutionauthor | [0-Belirlenecek] | |
dc.department-temp | [Ljungman, Per; Mielke, Stephan] Karolinska Univ Hosp Huddinge, Karolinska Comprehens Canc Ctr, Dept Cellular Therapy & Allogene Stem Cell Transp, Stockholm, Sweden; [Ljungman, Per] Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm, Sweden; [de la Camara, Rafael; Aguado, Beatriz] Hosp Princesa, Dept Hematol, Madrid, Spain; [Mikulska, Malgorzata] Univ Genoa, Div Infect Dis, Genoa, Italy; [Mikulska, Malgorzata] Osped Policlin San Martino, Genoa, Italy; [Al Zahrani, Mohsen] King Abdul Aziz Med City, Riyadh, Saudi Arabia; [Apperley, Jane] Imperial Coll, Ctr Haematol, London, England; [Berceanu, Ana] Hop Jean Minjoz, Besancon, France; [Bofarull, Rodrigo Martino] Hosp Santa Creu & Sant Pau, Barcelona, Spain; [Calbacho, Maria] Hosp Univ 12 Octubre, Madrid, Spain; [Ciceri, Fabio] Osped San Raffaele Srl, Milan, Italy; [Lopez-Corral, Lucia] Complejo Asistencial Univ Salamanca IBSAL, Ctr Invest Canc IBMCC, Hematol Dept, Salamanca, Spain; [Crippa, Claudia] Spedali Civil Brescia, Brescia, Italy; [Fox, Maria Laura] Vall dHebron Hosp Univ, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Serv Hematol,Expt Hematol, Barcelona, Spain; [Grassi, Anna] ASST Papa Giovanni XXIII, Bergamo, Italy; [Jimenez, Maria-Jose] ICO Hosp Germans Trias & Pujol, Josep Carreras Res Inst, Badalona, Spain; [Demir, Safiye Koculu] Demiroglu Bilim Univ, HSCT Unit, Istanbul, Turkey; [Kwon, Mi] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanit Gregorio Maranon, Madrid, Spain; [Llamas, Carlos Vallejo] Hosp Univ Donostia, San Sebastian, Spain; [Lorenzo, Jose Luis Lopez] Fdn Jimenez Diaz, Madrid, Spain; [Mielke, Stephan] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Orchard, Kim] Southampton Gen Hosp, Southampton, Hants, England; [Porras, Rocio Parody] ICO Hosp Duran i Reynals, Barcelona, Spain; [Vallisa, Daniele] Hosp Guglielmo Saliceto, Piacenza, Italy; [Xhaard, Alienor] Hop St Louis, Paris, France; [Knelange, Nina Simone] EBMT Data Off, Dept Med Stat & Bioinformat, Leiden, Netherlands; [Cedillo, Angel] GETH Spanish Registry, Madrid, Spain; [Kroger, Nicolaus] Univ Hosp Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany; [Pinana, Jose Luis] Hosp Clin Univ Valencia, Fdn Invest INCLIVA, Dept Hematol, Valencia, Spain; [Styczynski, Jan] Nicolaus Copernicus Univ Torun, Coll Med, Univ Hosp, Pediat Hematol & Oncol, Bydgoszcz, Poland | en_US |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
PubMed İndeksli Yayınlar Koleksiyonu [1488]
PubMed Indexed Publications Collection -
WoS İndeksli Yayınlar Koleksiyonu [2110]
WoS Indexed Publications Collection